Professor Trevor Robbins wins 'The Brain Prize'

RNS Number : 9515B
Cambridge Cognition Holdings PLC
11 March 2014
 



Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Professor Trevor Robbins wins 'The Brain Prize' 2014

 

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces that Professor Trevor Robbins CBE, co-inventor of CANTAB, has been awarded with the Grete Lundbeck European Brain Research Prize - 'The Brain Prize' 2014.

 

The Brain Prize recognises and rewards outstanding contributions to European neuroscience, from basic to clinical. Professor Robbins' research has spanned the areas of cognitive neuroscience, behavioural neuroscience and psychopharmacology. His main body of work has focused on the functions of the frontal lobes of the brain and their connections with other regions. 

 

It is this research that led to Robbins co-inventing the Cambridge Neuropsychological Test Automated Battery (CANTAB) with Professor Barbara Sahakian. The CANTAB computerised neuropsychological tests, are now used world-wide to sensitively conduct cognitive research by over 500 leading research institutions and assess the effectiveness and safety of new treatments in over 150 clinical trials.

 

Since its invention in 1986, CANTAB has been used to quantify mental and neurological function and its application in research has led to significant advances in our understanding of psychiatric and neurological conditions such as Parkinson's and Huntington's disease, dementia, schizophrenia, depression, drug addiction, obsessive-compulsive disorder and attention deficit/hyperactivity disorder. These discoveries are documented in over 1,300 peer-reviewed papers.

 

In winning The Brain Prize 2014, Professor Robbins' contribution to the advancement of neuroscience research has been recognised internationally and he joins an elite group of distinguished scientists to have won the accolade. The accolade follows Robbins' appointment as Commander of the Order of the British Empire (CBE) in 2012 for services to medical research.

 

Dr Andy Blackwell, Chief Scientific Officer at Cambridge Cognition who trained under Professors Robbins and Sahakian, commented: "All the team at Cambridge Cognition are thrilled and delighted that Professor Robbins has been awarded The Brain Prize. He has inspired, motivated and mentored a generation of cognitive neuroscientists and we are honoured to work alongside him in translating his fundamental scientific discoveries into innovative healthcare technologies that improve patient lives."

 

For further information on The Grete Lundbeck European Brain Research Prize visit www.thebrainprize.org   

View abstracts from over 180 CANTAB research papers by Professor Robbins at www.cambridgecognition.com/bibliography 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Nick Kerton, Chief Executive Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer




finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Matthew Robinson/Henrik Persson/Simon Hicks

(Corporate Finance)

Simon Starr

(Corporate Broking)



Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07584 391 303

Lianne Cawthorne

Mob: 07584 391 303

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.  The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABLGDXSSBBGSG
Investor Meets Company
UK 100